A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: DCY636, Placebo.
- Who it may be relevant to
- Registry conditions: Dermatitis, Atopic. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Japan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Two-part, Randomized, Participant- and Investigator-blinded, Placebo Controlled First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of DCY636 in a Single Ascending Dose Part in Healthy Participants and in a Multiple Dose Part in Participants With Moderate to Severe Atopic Dermatitis
Overview
The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.
Detailed description
This is a two-part FIH, randomized, placebo-controlled, participant- and investigator-blinded study in healthy participants (Part 1) and participants with moderate to severe AD (Part 2).
Interventions
- Drug DCY636
Participants will receive DCY636 - Drug Placebo
Participants will receive Placebo
Primary outcome measures
- Part 1-Incidence of adverse events (AEs) and serious adverse events (SAEs) [Time frame: Up to approximately 202 days]
- Part 2-Incidence of adverse events (AEs) and serious adverse events (SAEs) [Time frame: Up to approximately 301 days]
Secondary outcome measures (6)
- Part 1-Pharmacokinetic (PK) parameter: Cmax of DCY636 [Time frame: up to Day 202]
- Part 1-Pharmacokinetic (PK) parameter: AUC of DCY636 [Time frame: up to Day 202]
- Part 1-Anti-drug antibodies against DCY636 [Time frame: up to Day 202]
- Part 2-Pharmacokinetic (PK) parameter: Cmax of DCY636 [Time frame: up to Day 301]
- Part 2-Pharmacokinetic (PK) parameter: AUC of DCY636 [Time frame: up to Day 301]
- Part 2-Anti-drug antibodies against DCY636 [Time frame: up to Day 301]
Eligibility criteria
Inclusion criteria
Healthy Participants (Part 1)
- Healthy male and non-childbearing potential female participants 18 to 55 years of age inclusive.
Participants with moderate to severe atopic dermatitis (Part 2)
- Males and non-pregnant females age 18 years or older
- Diagnosis of atopic dermatitis for at least 1 year not adequately controlled by topicals
- Moderate to severe atopic dermatitis as defined by all of the following:
- EASI score ≥12 at screening visit and ≥16 at baseline (BL) visit
- IGA score ≥3 at screening visit and baseline visit
- Total Body surface area (BSA) affected by AD ≥ 10 % at screening visit and baseline visit
- Peak Pruritus NRS score ≥4 at baseline visit, based on weekly average of daily assessment in the week prior to baseline visit
Exclusion criteria
All Participants (Part 1, Part 2)
- Use of other investigational drugs within the last 30 days or 5 half-lives of the other drugs prior to initial dosing, whichever is longer.
- Meet any of the prohibited medication use criteria at baseline visit.
- A positive syphilis test result during screening period.
- Evidence of active or latent TB infection, as determined by T-Spot test during screening period.
- History of immunodeficiency diseases, or a positive human immunodeficiency virus (HIV) test result.
- Recent (within last half year) or ongoing helminth infection.
- History of hepatitis B or hepatitis C or serologic evidence for viral hepatitis. A positive Hepatitis B virus surface antigen (HBsAg), Hepatitis B virus core antibody (HBcAb) and/or Hepatitis B surface antibody (HBsAb) test during screening period excludes a participant. A positive test for HBsAb can be included if the test for HBsAg and HBcAb are negative and the history of hepatitis B vaccination is known. Participants with a positive Hepatitis C virus (HCV) antibody test should be excluded.
Healthy Participants (Part 1)
- Women of childbearing potential
- Smokers Participants with moderate to severe atopic dermatitis (Part 2)
- Regular use (more than 2 visits per week) of a tanning booth/parlor or extended sun exposure (per investigator judgement) within 4 weeks prior to baseline visit
- Have any chronic, uncontrolled medical condition, which would put the participant at increased risk during study participation, such as uncontrolled: diabetes, hypertension, morbid obesity, thyroid, adrenal, cardiovascular, pulmonary, hepatic, renal, neurologic or psychiatric disease, or other disease of concern, as per investigator judgment
- Women of childbearing potential (WOCBP) are excluded unless they are using highly effective methods of contraception (failure rate < 1% per year) while taking study treatment and for 202 days (= 5 times the terminal half-life) of study treatment after stopping study treatment.
Other protocol-defined inclusion/exclusion criteria may apply.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Japan · 1 center
- Novartis Investigative Site — Fukuoka
Identifiers
NCT: NCT07604324 · CDCY636A02101